ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 853

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases

Antoine G. Sreih1, Narender Annapureddy2, Kevin Byram3, George Casey4, Vince Frangiosa5, Michael George6, Sapna Sangani7, Rebecca Sharim5 and Peter A. Merkel8, 1Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology and Immunology, Vanderbilt University, Nashville, TN, 3Internal Medicine, Vanderbilt University, Nashville, TN, 4The Vasculitis Foundation, Kansas City, MO, 5Rheumatology, University of Pennsylvania, Philadelphia, PA, 6Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, 7Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 8Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Health Information Technology, phenotypes and vasculitis, Wegener's granulomatosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
To facilitate clinical care and research, validated algorithms are needed to
accurately identify patients with granulomatosis with
polyangiitis (GPA; Wegener’s). This study, sought to
evaluate and validate case-finding algorithms for GPA in 2 large health
administrative databases.

Methods: 250
patients were randomly selected from 2 large healthcare systems (125 patients
per system) using the International Classification of Diseases version 9 (ICD9)
code for GPA: 446.4. Because eosinophilic granulomatosis with polyangiitis
(Churg-Strauss) shares the same ICD9 code with GPA, patients
who have ever had ICD9 codes 288.3 (eosinophilia) or 493.*
(asthma) were excluded. 30 case-finding algorithms were constructed using a
combination of ICD9 code, encounter type (1 inpatient
ICD9 code on 3 consecutive days or 2 outpatient ICD9 codes 3 months apart), physician
specialty (Rheumatology, Nephrology, Pulmonology, or Otorhinolaryngology), use
of immunosuppressive medications, and whether an ANCA test was ordered. 2 time
periods for ICD9 code submission were examined: 1 year and 2 years. The
diagnosis was confirmed by chart review using the modified ACR classification
criteria or the Chapel Hill Consensus Conference definitions for GPA. Patients
who did not have a clear diagnosis were excluded from the analysis.

Results: 97
patients from the first healthcare system (site 1) and 98 patients from the second
system (site 2) were included in the analysis after excluding patients with
unclear diagnosis. 38/97 (39%) patients had a confirmed diagnosis of GPA at site
1 and 66/98 (67%) patients at site 2. Table 1 shows the positive and negative
predictive values of the studied algorithms in each healthcare system. An
algorithm excluding patients with eosinophilia or asthma and including the encounter
type and the physician specialty had the highest average positive predictive value
(PPV: 87.1%). An algorithm excluding patients with eosinophilia or asthma and including
the physician specialty had the highest average negative predictive value (NPV:
83.1%). There were no differences between the 2 time periods with regards to
the algorithms’ PPV or NPV.

Conclusion:
Case-finding algorithms can accurately identify patients with GPA using large administrative
databases. A simple algorithm excluding patients with eosinophilia or asthma
and including the encounter type and the physician specialty has the highest
positive predictive value. Similarly, an algorithm excluding patients with
eosinophilia or asthma and including the physician specialty has the highest
negative predictive value. These algorithms can be used to assemble population-based
cohorts of patients with GPA and facilitate future research in healthcare use, outcomes,
and comparative effectiveness. 

Table 1. Test characteristics
of the GPA algorithms in both healthcare systems

GPA Algorithms

Site 1 (n=97)

Site 2 (n=98)

PPV

NPV

PPV

NPV

ICD9+

46.2

94.1

72.9

69.2

   Encounter

58.3

79.6

90.8

78.8

   Specialty**

77.1

82.3

91.0

83.9

   Medications

64.4

82.7

78.5

78.9

   ANCA

68.0

70.8

82.5

66.7

ICD9+Encounter+

   Specialty*

82.1

78.3

92.1

77.1

   Medications

71.0

75.8

90.8

78.8

   ANCA

78.8

70.5

91.5

69.2

   Specialty+Medications

80.0

75.0

92.1

77.1

   Specialty+ANCA

82.4

70.0

91.5

69.2

   Medications+ANCA

75.0

67.9

91.5

69.2

   Specialty+Medications+ANCA

80.0

68.3

81.8

79.7

ICD9+Specialty+

   Medications

77.4

78.8

91.0

83.9

   ANCA

78.9

70.5

90.3

72.2

   Medications+ANCA

81.2

69.1

90.3

72.2

ICD9+Medications+

   ANCA

70.0

68.8

83.6

67.7

ICD9+Encounter+

   (1 year)

52.4

69.6

89.8

66.7

   (2 years)

52.4

70.9

89.8

66.7

   Specialty (1 year)

78.3

73.0

91.4

67.5

   Specialty (2 years)

79.2

74.0

91.4

67.5

   Medications (1 year)

67.9

72.5

89.8

66.7

   Medications (2 years)

67.9

72.5

89.8

66.7

   ANCA (1 year)

75.0

67.9

90.7

61.4

   ANCA (2 years)

76.5

68.8

90.7

61.4

   Specialty+Medications (1 year)

77.3

72.0

91.4

67.5

   Specialty+Medications (2 years)

77.3

72.0

91.4

67.5

   Specialty+ANCA (1 year)

80.0

68.3

90.7

61.4

   Specialty+ANCA (2 years)

81.2

69.1

90.7

61.4

   Specialty+Medications+ANCA (1 year)

80.0

68.3

90.7

61.4

   Specialty+Medications+ANCA (2 years)

80.0

68.3

90.7

61.4

* Algorithm with the highest average PPV ** Algorithm with the highest average NPV.

PPV: positive predictive value. NPV: negative predictive value. ICD9: ICD9 code 446.4 excluding ICD9 code 288.3 (eosinophilia) or ICD9 code 493.* (asthma). ENCOUNTER: 1 inpatient ICD9 code on 3 consecutive days or 2 outpatient ICD9 codes 3 months apart. SPECIALTY: a Rheumatologist, Pulmonologist, Otorhinolaryngologist, or a Nephrologist involved in the care of the patient. MEDICATIONS: an immunosuppressive medication used. ANCA: ANCA test ordered.

1 year: encounter ICD9 codes submitted within 12 months. 2 years: encounter ICD9 codes submitted within 24 months.



Disclosure: A. G. Sreih, None; N. Annapureddy, None; K. Byram, None; G. Casey, None; V. Frangiosa, None; M. George, None; S. Sangani, None; R. Sharim, None; P. A. Merkel, None.

To cite this abstract in AMA style:

Sreih AG, Annapureddy N, Byram K, Casey G, Frangiosa V, George M, Sangani S, Sharim R, Merkel PA. Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-and-validation-of-case-finding-algorithms-for-the-identification-of-patients-with-granulomatosis-with-polyangiitis-in-large-healthcare-administrative-databases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-and-validation-of-case-finding-algorithms-for-the-identification-of-patients-with-granulomatosis-with-polyangiitis-in-large-healthcare-administrative-databases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology